	te: <u>Nov. 16th, 2023</u>		
	ur Name: <u>James Yu</u>		
		•	g Adjuvant Treatment in Resected Stage III Cholangiocarcinoma
M	anuscript number (if known)	: <u>JGO-23-815</u>	
In	the interest of transparency	, we ask you to disclose all	I relationships/activities/interests listed below that are
re	ated to the content of your	manuscript. "Related" me	ans any relation with for-profit or not-for-profit third
pa	rties whose interests may be	e affected by the content o	of the manuscript. Disclosure represents a commitment
to	transparency and does not i	necessarily indicate a bias.	If you are in doubt about whether to list a
re	ationship/activity/interest,	it is preferable that you do) so.
		to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	anuscript only.		
-1			defined by the first order of the second section of the section of th
			defined broadly. For example, if your manuscript pertains
		- ·	all relationships with manufacturers of antihypertensive
me	edication, even if that medic	cation is not mentioned in t	the manuscript.
	-		d in this manuscript without time limit. For all other items,
th	e time frame for disclosure i	s the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		†
	medical writing, article		
	processing charges, etc.)		

Time frame: past 36 months

_X__None

_X__None

_X__None

No time limit for this item.

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

2

4

	1	I	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Passint of aquinment	V None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Plo	ease summarize the above c	onflict of interest in the fol	lowing box:
	None.		
- 1			

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov.					
Manuscript Tit	our Name: <u>Trenton A. Avriett</u> // Anuscript Title: Circulating Tumor DNA Analysis Guiding Adjuvant Treatment in Resected Stage III Cholangiocarcinoma // Anuscript number (if known): <u>JGO-23-815</u>				
related to the parties whose to transparence	of transparency, we ask you to disclose all relationships/activities/interests listed below that are content of your manuscript. "Related" means any relation with for-profit or not-for-profit third interests may be affected by the content of the manuscript. Disclosure represents a commitment y and does not necessarily indicate a bias. If you are in doubt about whether to list a ctivity/interest, it is preferable that you do so.				
The following manuscript on	questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> ly.				

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	X None	
0	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
	, , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11		V. None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Dlag	aa augumagisa tha ahaya aa		audea bays

Please summarize the above conflict of interest in the following box:

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: Nov. Your Name:	Christopher M. Ray
•	le: Circulating Tumor DNA Analysis Guiding Adjuvant Treatment in Resected Stage III Cholangiocarcinoma mber (if known): <u>JGO-23-815</u>
related to the	of transparency, we ask you to disclose all relationships/activities/interests listed below that are content of your manuscript. "Related" means any relation with for-profit or not-for-profit third interests may be affected by the content of the manuscript. Disclosure represents a commitment
to transparenc	y and does not necessarily indicate a bias. If you are in doubt about whether to list a commitment in the indicate a bias. If you are in doubt about whether to list a citivity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca pharmaceutical industry company	Participation and compensation through AZ's speakers bureau 2022-2023
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

Participation and compensation through AZ's speakers bureau 2022-2023

Please place an "X" next to the following statement to indicate your agreement:

Date: _	N	ov. 16	.6 th , 2023	
Your N	ame	:	Richard Kim	
Manus	cript	Title:	e: Circulating Tumor DNA Analysis Guiding Adjuvant Treatment in Resected Stage	III Cholangiocarcinoma
Manus	cript	numb	nber (if known): <u>JGO-23-815</u>	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	AstraZeneca, Exelixis, Ipsen, Eisai, Roche, and Pfizer	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Incyte and AstraZeneca	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

The author received consulting/advisory fees from AstraZeneca, Exelixis, Ipsen, Eisai, Roche, and Pfizer and Speakers Bureau fees from Incyte and AstraZeneca

Please place an "X" next to the following statement to indicate your agreement: